Parion Sciences Overview
- Year Founded
-
2000
- Status
-
Private
- Employees
-
14
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$274K
- Investors
-
4
Parion Sciences General Information
Description
Operator of a development stage company intended to research, develop, and commercialize treatments for diseases with unmet medical needs. The company's technologies target respiratory, ocular, and other epithelial diseases resulting from the patient's ability to protect their mucosal surfaces being compromised, enabling healthcare professionals to restore a patient's innate mucosal defense system.
Contact Information
Website
www.parion.comCorporate Office
- 2800 Meridian Parkway
- Suite 195
- Durham, NC 27713
- United States
Corporate Office
- 2800 Meridian Parkway
- Suite 195
- Durham, NC 27713
- United States
Parion Sciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Grant | 27-Jan-2020 | $274K | 000.00 | Completed | Clinical Trials - Phase 2 | |
| 10. Grant | 16-Sep-2014 | 000 | 000.00 | Completed | Clinical Trials - Phase 2 | |
| 9. Grant | 01-Jan-2013 | 00.000 | 000.00 | Completed | Startup | |
| 8. Grant | 01-Jan-2011 | 00.00 | 000.00 | Completed | Startup | |
| 7. Grant | 01-Jan-2010 | 00000 | 000.00 | Completed | Startup | |
| 6. Grant | 01-Jan-2009 | 00000 | 000.00 | Completed | Startup | |
| 5. Grant | 01-Jan-2006 | 00000 | 000.00 | Completed | Startup | |
| 4. Later Stage VC (Series C) | 10-Jan-2005 | 000.00 | 000.00 | Completed | Startup | |
| 3. Grant | 01-Jan-2005 | $854K | $10.1M | Completed | Startup | |
| 2. Early Stage VC (Series B) | 07-Jul-2003 | $3.57M | $10.1M | Completed | Startup |
Parion Sciences Comparisons
Industry
Financing
Details
000000
00 000
Parion Sciences Competitors (52)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| XyloCor Therapeutics | Venture Capital-Backed | Wayne, PA | 00 | 000.00 | 00000000000 | 000.00 |
| G1 Therapeutics | Formerly VC-backed | Durham, NC | 000 | 00000 | 000000&0 | 00000 |
| Visterra | Formerly VC-backed | Waltham, MA | 000 | 00000 | 000000&0 | 00000 |
| NexImmune | Formerly VC-backed | Gaithersburg, MD | 00 | 00000 | 00000000 | 00000 |
| Atox Bio | Venture Capital-Backed | Durham, NC | 00 | 000.00 | 000000 - 000 | 000.00 |
Parion Sciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Parion Sciences Patents
Parion Sciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023213626-A1 | Biphenyl-substituted epithelial sodium channel blocking compounds | Pending | 26-Jan-2022 | 0000000000 | |
| CA-3003780-A1 | Delivering osmolytes by nasal cannula | Inactive | 03-May-2018 | 000000000 | |
| US-10526283-B2 | Prodrugs of dithiol mucolytic agents | Inactive | 30-Apr-2015 | 0000000000 | 000 |
| AU-2016255851-A1 | Novel prodrugs of dithiol mucolytic agents | Inactive | 30-Apr-2015 | 0000000000 | |
| EP-3288548-A1 | Novel prodrugs of dithiol mucolytic agents | Inactive | 30-Apr-2015 | C07C327/28 |
Parion Sciences Executive Team (6)
| Name | Title | Board Seat |
|---|---|---|
| Paul Boucher | President, Chief Executive Officer & Board Member | |
| Richard Boucher MD | Co-Founder & Chairman | |
| Aaron Farmand | Vice President, Finance & Administration |
Parion Sciences Board Members (4)
| Name | Representing | Role | Since |
|---|---|---|---|
| Paul Boucher | Parion Sciences | President, Chief Executive Officer & Board Member | 000 0000 |
| Richard Boucher MD | Parion Sciences | Co-Founder & Chairman | 000 0000 |
| Robert Wills Ph.D | Self | Board Member | 000 0000 |
Parion Sciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Parion Sciences Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| National Institute for Allergy and Infectious Disease | Government | 000 0000 | 000000 0 | |
| Cystic Fibrosis Foundation | Limited Partner | 000 0000 | 000000 0 | |
| National Heart, Lung, and Blood Institute | Government | 000 0000 | 000000 0 | |
| U.S. Department of Health and Human Services | Government | 000 0000 | 000000 0 |
Parion Sciences FAQs
-
When was Parion Sciences founded?
Parion Sciences was founded in 2000.
-
Who is the founder of Parion Sciences?
Richard Boucher MD and Ross Johnson Ph.D are the founders of Parion Sciences.
-
Who is the CEO of Parion Sciences?
Paul Boucher is the CEO of Parion Sciences.
-
Where is Parion Sciences headquartered?
Parion Sciences is headquartered in Durham, NC.
-
What is the size of Parion Sciences?
Parion Sciences has 14 total employees.
-
What industry is Parion Sciences in?
Parion Sciences’s primary industry is Drug Discovery.
-
Is Parion Sciences a private or public company?
Parion Sciences is a Private company.
-
What is Parion Sciences’s current revenue?
The current revenue for Parion Sciences is 000000.
-
How much funding has Parion Sciences raised over time?
Parion Sciences has raised $22.1M.
-
Who are Parion Sciences’s investors?
National Institute for Allergy and Infectious Disease, Cystic Fibrosis Foundation, National Heart, Lung, and Blood Institute, and U.S. Department of Health and Human Services have invested in Parion Sciences.
-
Who are Parion Sciences’s competitors?
XyloCor Therapeutics, G1 Therapeutics, Visterra, NexImmune, and Atox Bio are some of the 52 competitors of Parion Sciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
